Type II transmembrane serine proteases as potential target for anti-influenza drug discovery

Woo Jin Shin, Baik Lin Seong

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: The outbreak of an influenza pandemic as well as the continued circulation of seasonal influenza highlights the need for effective antiviral therapies. The emergence of drug-resistant strains further necessitates the development of novel antivirals that target the host factors crucial for viral replication. Area covered: This review summarizes the current understanding of the structural and functional properties of type II transmembrane serine proteases (TTSPs) as a proteolytic activator of influenza virus infection and discusses their potential as antiviral targets. It also explores the experimental evidence accumulated for inhibitors of TTSPs as novel, broad-spectrum antivirals against various influenza virus subtypes. The review also provides an overview of the properties of small molecules, proteins, and peptides that efficiently inhibit the proteolytic activation of the influenza virus. Expert opinion: TTSPs activate a wide range of influenza virus subtypes including avian influenza viruses, both in vitro and in vivo, via proteolytic cleavage of influenza hemagglutinin (HA) into infection-competent fusogenic conformation. Other viruses such as SARS-, MERS-coronaviruses and human metapneumoviruses may use the same host cell proteases for activation, implying that TTSP inhibition might be a novel strategy for developing broad-spectrum antiviral agents for respiratory viral infections.

Original languageEnglish
Pages (from-to)1139-1152
Number of pages14
JournalExpert Opinion on Drug Discovery
Volume12
Issue number11
DOIs
Publication statusPublished - 2017 Nov 2

Fingerprint

Serine Proteases
Drug Discovery
Orthomyxoviridae
Human Influenza
Antiviral Agents
Virus Diseases
SARS Virus
Metapneumovirus
Influenza in Birds
Expert Testimony
Hemagglutinins
Pandemics
Respiratory Tract Infections
Disease Outbreaks
Peptide Hydrolases
Viruses
Peptides
Infection
Pharmaceutical Preparations
Proteins

All Science Journal Classification (ASJC) codes

  • Drug Discovery

Cite this

@article{086a4606052745098bb8f8f7c62e5c23,
title = "Type II transmembrane serine proteases as potential target for anti-influenza drug discovery",
abstract = "Introduction: The outbreak of an influenza pandemic as well as the continued circulation of seasonal influenza highlights the need for effective antiviral therapies. The emergence of drug-resistant strains further necessitates the development of novel antivirals that target the host factors crucial for viral replication. Area covered: This review summarizes the current understanding of the structural and functional properties of type II transmembrane serine proteases (TTSPs) as a proteolytic activator of influenza virus infection and discusses their potential as antiviral targets. It also explores the experimental evidence accumulated for inhibitors of TTSPs as novel, broad-spectrum antivirals against various influenza virus subtypes. The review also provides an overview of the properties of small molecules, proteins, and peptides that efficiently inhibit the proteolytic activation of the influenza virus. Expert opinion: TTSPs activate a wide range of influenza virus subtypes including avian influenza viruses, both in vitro and in vivo, via proteolytic cleavage of influenza hemagglutinin (HA) into infection-competent fusogenic conformation. Other viruses such as SARS-, MERS-coronaviruses and human metapneumoviruses may use the same host cell proteases for activation, implying that TTSP inhibition might be a novel strategy for developing broad-spectrum antiviral agents for respiratory viral infections.",
author = "Shin, {Woo Jin} and Seong, {Baik Lin}",
year = "2017",
month = "11",
day = "2",
doi = "10.1080/17460441.2017.1372417",
language = "English",
volume = "12",
pages = "1139--1152",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "11",

}

Type II transmembrane serine proteases as potential target for anti-influenza drug discovery. / Shin, Woo Jin; Seong, Baik Lin.

In: Expert Opinion on Drug Discovery, Vol. 12, No. 11, 02.11.2017, p. 1139-1152.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Type II transmembrane serine proteases as potential target for anti-influenza drug discovery

AU - Shin, Woo Jin

AU - Seong, Baik Lin

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Introduction: The outbreak of an influenza pandemic as well as the continued circulation of seasonal influenza highlights the need for effective antiviral therapies. The emergence of drug-resistant strains further necessitates the development of novel antivirals that target the host factors crucial for viral replication. Area covered: This review summarizes the current understanding of the structural and functional properties of type II transmembrane serine proteases (TTSPs) as a proteolytic activator of influenza virus infection and discusses their potential as antiviral targets. It also explores the experimental evidence accumulated for inhibitors of TTSPs as novel, broad-spectrum antivirals against various influenza virus subtypes. The review also provides an overview of the properties of small molecules, proteins, and peptides that efficiently inhibit the proteolytic activation of the influenza virus. Expert opinion: TTSPs activate a wide range of influenza virus subtypes including avian influenza viruses, both in vitro and in vivo, via proteolytic cleavage of influenza hemagglutinin (HA) into infection-competent fusogenic conformation. Other viruses such as SARS-, MERS-coronaviruses and human metapneumoviruses may use the same host cell proteases for activation, implying that TTSP inhibition might be a novel strategy for developing broad-spectrum antiviral agents for respiratory viral infections.

AB - Introduction: The outbreak of an influenza pandemic as well as the continued circulation of seasonal influenza highlights the need for effective antiviral therapies. The emergence of drug-resistant strains further necessitates the development of novel antivirals that target the host factors crucial for viral replication. Area covered: This review summarizes the current understanding of the structural and functional properties of type II transmembrane serine proteases (TTSPs) as a proteolytic activator of influenza virus infection and discusses their potential as antiviral targets. It also explores the experimental evidence accumulated for inhibitors of TTSPs as novel, broad-spectrum antivirals against various influenza virus subtypes. The review also provides an overview of the properties of small molecules, proteins, and peptides that efficiently inhibit the proteolytic activation of the influenza virus. Expert opinion: TTSPs activate a wide range of influenza virus subtypes including avian influenza viruses, both in vitro and in vivo, via proteolytic cleavage of influenza hemagglutinin (HA) into infection-competent fusogenic conformation. Other viruses such as SARS-, MERS-coronaviruses and human metapneumoviruses may use the same host cell proteases for activation, implying that TTSP inhibition might be a novel strategy for developing broad-spectrum antiviral agents for respiratory viral infections.

UR - http://www.scopus.com/inward/record.url?scp=85030468747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030468747&partnerID=8YFLogxK

U2 - 10.1080/17460441.2017.1372417

DO - 10.1080/17460441.2017.1372417

M3 - Review article

C2 - 28870104

AN - SCOPUS:85030468747

VL - 12

SP - 1139

EP - 1152

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 11

ER -